2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-119971
    BIM5078 337506-43-1 98%
    BIM5078 is a hepatocyte nuclear factor 4α (HNF4α) antagonist that can inhibit the expression of known HNF4α target genes. BIM5078 represses insulin promoter activity through HNF4α antagonism. BIM5078 can be used for the research of cancer and diabetes.
    BIM5078
  • HY-119982
    Cyclamide 664-95-9 98%
    Cyclamide (Cicloral), an oligopeptide, can be produced by cyanobacteria algae strains. Cyclamide can be used for the research of diabetes mellitus.
    Cyclamide
  • HY-120057
    CP-331684 207922-70-1 98%
    CP-331684 is an orally active agonist of β3-Adrenergic receptor. CP-331684 can be studied in research on obesity.
    CP-331684
  • HY-120082
    FR-182980 179054-51-4 98%
    FR-182980 is an orally active ACAT1 inhibitor (IC50: 30 nM). FR-182980 has hypocholesterolemic activity and can be used for research of atherosclerosis.
    FR-182980
  • HY-120126
    ML378 1831135-21-7 98%
    ML378 (CID71710938) is a dual LYPLA1 and LYPLA2 inhibitor, with IC50s of 122 nM and 245 nM respectively. ML378 also shows potent inhibition of ABHD6 (IC50 = 3.15 nM). ML378 can be used for elucidating the patho/physiological roles of the LYPLA1 and LYPLA2.
    ML378
  • HY-120148
    SM19712 free acid 194542-49-9 98%
    SM19712 free acid is an orally active, selective endothelin converting enzyme (ECE) inhibitor. SM19712 free acid inhibits conversion of big ET-1 to ET-1. SM19712 free acid attenuates colonic angiogenesis, tissue injury, inflammation, without altering colon shortening or myeloperoxidase levels in mice. SM19712 free acid can be used for the research of inflammatory bowel disease (colitis), ischemic acute renal failure, acute myocardial infarction, and myocardial ischemia/reperfusion injury.
    SM19712 free acid
  • HY-120171
    DH-376 1848233-57-7 98%
    DH-376 is a potent diacylglycerol lipase inhibitor with pIC50 values of 8.6 and 8.9 for ABHD6 and DAGLα, respectively. DH-376 prevents fasting-induced refeeding of mice. DH-376 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    DH-376
  • HY-120223
    BMS-196085 170686-10-9 98%
    BMS-196085 is an orally active, potent and selective full agonist against human β3 adrenergic receptor with a Ki value of 21 nM. BMS-196085 also has partial agonist activity at the β1 receptor. BMS-196085 is promising for research of obesity and type-II diabetes.
    BMS-196085
  • HY-120270
    PF-06679142 1467059-66-0 98%
    PF-06679142 (Compound 10) is a potent, orally active AMPK activator with an EC50 of 22 nM against α1β1γ1-AMPK. PF-06679142 can be used for diabetic nephropathy research.
    PF-06679142
  • HY-120273
    Glucocorticoids receptor agonist 3 305821-96-9 98%
    Glucocorticoids receptor agonist 3 is a potent agonist of glucocorticoids receptor. Glucocorticoids receptor agonist 3 is useful to research diseases, such as obesity, diabetes, and inflammation (extracted from patent WO2000066522A1, compound 345).
    Glucocorticoids receptor agonist 3
  • HY-120288
    AM4299B 160825-49-0 98%
    AM4299B is an inhibitor for thiol protease. AM4299B inhibits bovine spleen cathepsin B, human kidney cathepsin L and papain with IC50s of 0.7, 0.5 and 20 μM, respectively. AM4299B can be used in research in osteoporosis, and has potential to be used as an antiparasitic agent.
    AM4299B
  • HY-120300
    UCM710 213738-77-3 98%
    UCM710 is an endocannabinoid (eCB) hydrolysis inhibitor that increases the levels of N-arachidonoyl ethanolamine and 2-arachidonoylglycerol in neurons. UCM710 inhibits fatty acid amide hydrolase and α/β-hydrolase domain 6, but not monoacylglycerol lipase.
    UCM710
  • HY-120302
    PD 140376 149027-97-4 98%
    PD 140376 is a potent antagonist for the cholecystokininB/gastrin receptor, with Ki values of 0.18 nM and 0.21 nM in guinea-pig cortex and gastric gland membranes, respectively.
    PD 140376
  • HY-120358
    L-6424 147030-50-0 98%
    L-6424 inhibits T3 binding to α1-T3R and β1-T3R.
    L-6424
  • HY-120374
    V-PYRRO/NO 179344-98-0 98%
    V-PYRRO/NO is a NO donor in vivo. Following hepatic metabolism, it spontaneously decomposes with a half-life of 3 seconds to liberate NO.
    V-PYRRO/NO
  • HY-120401
    Glybuzole 1492-02-0 98%
    Glybuzole (Desaglybuzole) is an orally effective hypoglycemic agent. Glybuzole promotes insulin secretion by pancreatic β cells and inhibits glucagon secretion by pancreatic α cells. Glybuzole reduces blood glucose levels as well as arginine-stimulated plasma glucagon levels. Glybuzole can be used in diabetes-related research.
    Glybuzole
  • HY-120455
    PD 125967 128139-14-0 98%
    PD 125967 is an oligopeptide renin inhibitor. PD 125967 can be used to low blood pressure.
    PD 125967
  • HY-120473
    TAK-259 1192348-73-4 98%
    TAK-259 is an orally active α1D-adrenergic receptor antagonist with a Ki value of 1.1 nM for human α1D-adrenergic receptors. TAK-259 can inhibit the contraction of isolated bladder strips in rats with bladder outlet obstruction, reduce non-voiding bladder contractions, and improve urinary frequency symptoms. TAK-259 can be used in research related to overactive bladder.
    TAK-259
  • HY-12048R
    Chelerythrine chloride (Standard) 3895-92-9
    Chelerythrine (chloride) (Standard) is the analytical standard of Chelerythrine (chloride). This product is intended for research and analytical applications. Chelerythrine chloride is a potent, cell-permeable inhibitor of protein kinase C, with an IC50 of 660 nM. Chelerythrine chloride inhibits the Bcl-XL-Bak BH3 peptide binding with IC50 of 1.5 μM and displaces Bax from Bcl-XL. Chelerythrine chloride induces apoptosis and autophagy.
    Chelerythrine chloride (Standard)
  • HY-120493
    (rel)-AM-6226 1142222-28-3 98%
    (rel)-AM-6226 is the relative stereoisomer of AM-6226 (HY-120493A). AM-6226 is a potent, orally active full agonist of G protein-coupled receptor 40 (GPR40) with an EC50 value of 0.12 μM. AM-6226 activates GPR40 receptors on pancreatic β-cells and enteroendocrine L-cells, promotes insulin secretion in a glucose-dependent manner, and increases the release of incretin hormones (GLP-1, GIP), thus avoiding the risk of hypoglycemia. AM-6226 can be used in the research of metabolic diseases such as diabetes.
    (rel)-AM-6226
Cat. No. Product Name / Synonyms Application Reactivity